摘要
菱形黑扇贫血(DBA)是一种遗传性红血球再生障碍性贫血,发病于儿童时期。患者携带19个核糖体蛋白(Rp)基因中的一个杂合子突变,导致核糖体缺陷。我的生物发生和功能。标准治疗包括类固醇或输血,但唯一的最终治疗方法是异基因造血干细胞移植(HSCT)。虽然H的进展SCT在过去几年中大大提高了成功率,不良事件的风险和死亡率仍然很高。 使用基因治疗的临床试验目前正在针对多种单基因疾病进行,基于干细胞的创新策略的开发可能为dba治疗开辟新的选择。也是在这篇综述中,我们总结了新的治疗方法在治疗这种疾病方面的最新进展。我们还介绍了不同的基于dna和rna的技术。作为新的候选药理治疗方法,并对其在治疗DBA方面的相关性和潜在适用性进行了探讨。
关键词: 骨髓衰竭综合征,菱形黑发贫血,基因编辑,基因治疗,核糖体蛋白,核糖体病。
Current Gene Therapy
Title:Emerging Therapeutic Approaches for Diamond Blackfan Anemia
Volume: 18 Issue: 6
关键词: 骨髓衰竭综合征,菱形黑发贫血,基因编辑,基因治疗,核糖体蛋白,核糖体病。
摘要: Diamond Blackfan Anemia (DBA) is an inherited erythroid aplasia with onset in childhood. Patients carry heterozygous mutations in one of 19 Ribosomal Protein (RP) genes, that lead to defective ribosome biogenesis and function. Standard treatments include steroids or blood transfusions but the only definitive cure is allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Although advances in HSCT have greatly improved the success rate over the last years, the risk of adverse events and mortality is still significant.
Clinical trials employing gene therapy are now in progress for a variety of monogenic diseases and the development of innovative stem cell-based strategies may open new alternatives for DBA treatment as well. In this review, we summarize the most recent progress toward the implementation of new therapeutic approaches for this disorder. We present different DNA- and RNA-based technologies as well as new candidate pharmacological treatments and discuss their relevance and potential applicability for the cure of DBA.
Export Options
About this article
Cite this article as:
Emerging Therapeutic Approaches for Diamond Blackfan Anemia, Current Gene Therapy 2018; 18 (6) . https://dx.doi.org/10.2174/1566523218666181109124538
DOI https://dx.doi.org/10.2174/1566523218666181109124538 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements